"Mr Edwards said there was potential for significant investment from organisations and governments around the world interested in developing new antibiotics development."
Clevegen shows good safety and potential to block Clever-1 on circulating monocytes
-- Wholly-owned Clevegen (FP-1305) shows no toxicity in dose escalation studies in large preclinical models
-- The no-observed-adverse-effect-level (NOAEL) was 100 mg/kg, which is roughly 30 times higher concentration than needed for Clever-1 occupancy in vivo
-- Clevegen also blocked Clever-1 on circulating monocytes as expected. The duration of blocking was dose dependent and resumed to normal level in 20 days in the highest dose
-- The Company expects CTA filing for MATINS study in Q3 2018 and first patient recruitment in Q4 2018